期刊文献+

胆管癌手术患者程序性死亡配体1的表达与患者中性粒细胞淋巴细胞比例的关系及其临床意义研究

Programmed Death-Ligand 1(PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma
下载PDF
导出
摘要 目的近年来胆管癌的发病率有逐渐增高的趋势,且缺乏有效的治疗手段。本研究旨在探讨胆管癌中PDL1的表达及作用。方法选取我院2015年1月至2017年5月间收治的46名接受手术切除肝外胆管癌患者,对其样本进行福尔马林固定石蜡包埋切片,用抗PD-L1抗体免疫组化染色评估PD-L1的表达。采用Fisher精确检验分析PD-L1和临床病理特征之间关联,采用Cox回归模型进行生存分析。结果在46个样本中,PD-L1在32个(70%)肿瘤细胞膜阳性表达。PD-L1表达的平均水平为1.75%(0-34.7)。PD-L1表达与IV期疾病(OR 3.98,P=0.046)和中性粒细胞/淋巴细胞比值(OR 5.36,P=0.018)显著相关。相对PD-L1阴性的肿瘤样本,PD-L1阳性与较差的总生存率有相关性,但未达到显著水平(7.2vs.7.9个月,P=0.32)。结论 PD-L1在胆管癌中广泛表达,但不能预测总生存期。PD-L1阳性与IV期疾病和高中性粒细胞/淋巴细胞比率呈显著相关。 Objective Effective treatments for cholangiocarcinoma(CCA)are still lacking.This study aimed to investigate the expression of PD-L1 and its relation to possible treatments for CCA.Methods 46 cases of patients with cholangiocarcinoma in our hospital from January 2015 to May 2017 were selected as study objects.Formalin-fixed paraffin-embedded tumor samples from the patients were retrieved.PD-L1 expression was evaluated by immunohistochemistry using anti-PD-L1 antibody.The association between PD-L1,clinico-pathological characteristics was analyzed using Fisher’s exact test,and survival analysis was done with the Cox regression model.Results Out of 46 samples,32(70%)had positive PD-L1 expression in tumor cell membranes.The median level of PD-L1 expression was 1.75%(0-34.7).PD-L1 expression was significantly associated with stage IV disease(OR 3.98,P=0.046)and a high neutrophil/lymphocyte ratio(OR 5.36,P=0.018).PD-L1 positivity was associated with worse overall survival compared with those with a PD-L1 negative tumor but did not reach a level of significance(7.2 vs.7.9 months,P=0.32).Conclusion PD-L1 is widely expressed in CCA but was not predictive for overall survival.PD-L1 positivity was significantly associated with stage IV disease and a high neutrophil/lymphocyte ratio.
作者 王金涛 张成 杨林 安东均 王羊 赵宝国 韩立 WANG Jin-tao;ZHANG Cheng;YANG Lin(Department of Hepatobiliary Surgery,Xianyang Central Hospital,Xianyang 712000,China)
出处 《中国实验诊断学》 2019年第6期963-966,共4页 Chinese Journal of Laboratory Diagnosis
基金 陕西省自然科学基础研究计划项目(2012JQ4016)
关键词 胆管癌 免疫研究 中性粒细胞/淋巴细胞比率 程序化死亡配体1 cholangiocarcinoma immune studies Neutrophil-Lymphocyte ratio PD-L1
  • 相关文献

参考文献1

二级参考文献23

  • 1Sasaki R,Takeda Y,Funato O,et al.Significance of ductal mar- gin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma[J].World J Surg,2007,31(9):1788-1796.
  • 2Nagahashi M,Shirai Y,Wakai T,et al.Depth of invasion deter- mines the postresectional prognosis for patients with Tl extrahepa- tic cholangiocarcinoma[J].Cancer,2010,116(2):400-405.
  • 3Nitta T,Mitsuhashi T,Hatanaka Y,et al.Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma:comprehensive immunohistochemical study using a tissue microarray[J].Br J Cancer,2014,111(7):1363-1372.
  • 4Oshiro Y,Sasaki R,Kobayashi A,et al.Prognostic relevance of the lymph node ratio in surgical patients with extrahepatic cholan- giocarcinoma[J].Eur J Surg Oncol,2011,37(1);60-64.
  • 5Wakai T,Shirai Y,Moroda T,et al.Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma[J].Cancer,2005,103(6):1210-1216.
  • 6Murphy G.The ADAMs:signalling scissors in the tumour micro- environment[J].Nat Rev Cancer,2008,8(12):929-941.
  • 7Blobel CP.ADAMs:key components in EGFR signalling and de- velopment[J].Nat Rev Mol Cell Biol,2005,6(1):32-43.
  • 8Xiao LJ,Lin P,Lin F,et al.ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion[J].Int J Oncol,2012,40(5):1714-1724.
  • 9Baumgart A,Seidl S,Vlachou P,et al.ADAM17 regulates epi- dermal growth factor receptor expression through the activation of Notchl in non-small cell lung cancer[J].Cancer Res,2010,70(13):5368-5378.
  • 10Shou ZX,Jin X,Zhao ZS.Upregulated expression of ADAM 17 is a prognostic marker for patients with gastric cancer[J].Ann Surg,2012,256(6):1014-1022.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部